| My Account | Subscribe | Contact Us | Donate |
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Related Medications Threads on Diabetes Health Forums
The Food and Drug Administration (FDA) just approved pre-filled pens for administering Symlin, which was previously available only in vials. The SymlinPen 60 delivers 15, 30, 45, or 60 micrograms per dose.
8 comments - Nov 14, 2007 -
Symlin, or pramlintide, is synthetic amylin, a natural hormone that slows stomach emptying and leads to a feeling of fullness. Currently Symlin is used to dampen blood sugar rises in people with diabetes, but it's showing potential as a weight loss drug as well, according to a recent study.
1 comment - Oct 12, 2007 -
As many of us know to our dismay, the desire to chow down fatty, sugary food can be very strong indeed. In a recent six-week study of 88 obese, non-diabetic men and women, Symlin, a synthetic hormone currently used to dampen diabetic blood sugar swings, was found to dampen those very desires.
2 comments - Jun 27, 2007 -
I recently had the privilege of interviewing Ginger Graham, the CEO who led Amylin during the launch of its two first-in-class medicines, Byetta and Symlin. A fascinating woman with a very personal leadership style, she had the following to say about her past achievements and her future hopes.
0 comments - Jun 1, 2007 -
On March 16, 2005, Amylin Pharmaceuticals, Inc., of San Diego, California, announced it had received FDA approval for Symlin (pramlintide acetate) injections to be used in conjunction with insulin to treat diabetes.
0 comments - Jun 1, 2005 -